The aim of this retrospective analysis was to determine the prognostic value of the time of developing motor deficits before radiotherapy (RT) and to confirm our preliminary results by achieving statistical significance. Of 529 patients receiving spinal irradiation (1994–1998) 131 fulfilled the selection criteria. Three groups were formed according to time of developing motor deficits: 1–7 days (n = 51), 8–14 days (40), >14 days (40). Motor function was graded before, 2 weeks and 3 months after RT. After 2 weeks, patients developing motor deficits for >14 days showed improvement more often than patients of the other groups (65 versus 32.5 and 4%, p < 0.001). After 3 months results were comparable (p < 0.001). A slower development of motor deficits predicts a better functional outcome. Time of developing motor deficits before RT is a relevant prognostic factor in metastatic spinal cord compression.

1.
Asdourian PL: Natural history of metastatic spinal disease; in Bridwell KH, DeWald RL (eds): Textbook of Spinal Surgery. Philadelphia, Lippincott-Raven, 1997, pp 2008–2015.
2.
Greenberg HS, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Results with a new treatment protocol. Ann Neurol 1980;8:361–366.
3.
Sørensen PS, Børgesen SE, Rohde K, Rasmusson B, Bach F, Bøge-Rasmussen T, Stjernholm P, Holt-Larsen B, Agerlin N, Gjerris F: Metastatic epidural spinal cord compression. Cancer 1990;65:1502–1509.
4.
Kim RY, Smith JW, Spencer SA, Meredith RF, Salter MM: Malignant epidural spinal cord compression associated with a paravertebral mass: Its radiotherapeutic outcome on radiosensitivity. Int J Radiat Oncol Biol Phys 1993;27:1079–1083.
5.
Maranzano E, Latini P: Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: Final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995;32:959–967.
6.
Leviov M, Dale J, Stein M, Ben-Shahar M, Ben-Arush M, Milstein D, Goldsher D, Kuten A: The management of metastatic spinal cord compression: A radiotherapeutic success ceiling. Int J Radiat Oncol Biol Phys 1993;27:231–234.
7.
Schiff D, Shaw EG, Cascino TL: Outcome after spinal reirradiation for malignant epidural spinal cord compression. Ann Neurol 1995;37:583–589.
8.
Helweg-Larsen S: Clinical outcome in metastatic spinal cord compression. Acta Neurol Scand 1996;94: 269–275.
9.
Helweg-Larsen S, Sørensen PS, Kreiner S: Prognostic factors in metastatic spinal cord compression: A prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. Int J Radiat Oncol Biol Phys 2000;46:1163–1169.
10.
Rades D, Blach M, Nerreter V, Bremer M, Karstens JH: Metastatic spinal cord compression: Influence of time between onset of motor deficits and start of irradiation on therapeutic effect. Strahlenther Onkol 1999;175:378–381.
11.
Helweg-Larsen S, Rasmusson B, Sørensen PS: Recovery of gait after radiotherapy in paralytic patients with metastatic epidural spinal cord compresssion. Neurology 1990;40:1234–1236.
12.
Wagner W, Prott FJ, Rübe C, Willich N: Strahlentherapie epiduraler Metastasen mit Rückenmarkskompression. Strahlenther Onkol 1996;172:604–609.
13.
Gilbert RW, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 1978;3:40–51.
14.
Wallington M, Mendis S, Premawardhana U, Sanders P, Shahsavar-Haghighi K: Local control and survival in spinal cord compression from lymphoma and myeloma. Radiother Oncol 1997;42:43–47.
15.
Baskin DS: Spinal cord injury; in Evans RW (ed): Neurology and Trauma. Philadelphia, Saunders, 1996, pp 276–299.
16.
Ushio Y, Posner R, Posner JB, Shapiro WR: Experimental spinal cord compression by epidural neoplasm. Neurology 1977;27:422–429.
17.
Kato A, Ushio Y, Hayakawa T, Yamada K, Ikeda H, Mogami H: Circulatory disturbance of the spinal cord with epidural neoplasm in rats. J Neurosurg 1985;63:260–265.
18.
Manabe S, Tanaka H, Higo Y, Park P, Ohno T, Tateishi A: Experimental analysis of the spinal cord compressed by spinal metastasis. Spine 1989;14:1308–1315.
19.
Hall ED, Braughler JM: Free radicals in CNS injury. Res Publ Assoc Res Nerv Ment Dis 1993;71:81–105.
20.
Kim RY, Spencer SA, Meredith RF, Weppelmann B, Lee JY, Smith JW, Salter MM: Extradural spinal cord compression: Analysis of factors determining functional prognosis – A prospective study. Radiology 1990;176:279–282.
21.
Maranzano E, Latini P, Checcaglini F, Ricci S, Panizza BM, Aristei C, Perrucci E, Beneventi S, Corgna E, Tonato M: Radiation therapy in metastatic spinal cord compression. Cancer 1991;67:1311–1317.
22.
Turner S, Marosszeky B, Timms I, Boyages J: Malignant spinal cord compression: A prospective evaluation. Int J Radiat Oncol Biol Phys 1993;26:141–146.
23.
Sørensen PS, Helweg-Larsen S, Mouridsen H, Hansen H: Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomised trial. Eur J Cancer 1994;30A:22–27.
24.
Helweg-Larsen S, Hansen SW, Sørensen PS: Second occurence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Int J Radiat Oncol Biol Phys 1995;33:595–598.
25.
Loblaw DA, Lapierre NJ: Emergency treatment of malignant extradural spinal cord compression: An evidence-based guideline. J Clin Oncol 1998;16:1613–1624.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.